Venous thromboembolism and nonsmall cell lung cancer-Reference-Cited by-同舟云学术

Venous thromboembolism and nonsmall cell lung cancer

Published:2009-12-01 Issue:23 Volume:115 Page:5516-5525
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hicks Lisa K.,Cheung Matthew C.,Ding Keyue,Hasan Baktiar,Seymour Lesley,Le MaÃ®tre AurÃ©lie,Leighl Natasha B.,Shepherd Frances A.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference37 articles.

1. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study;Heit;Arch Intern Med.,2000

2. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data;Levitan;Medicine (Baltimore).,1999

3. Haemostatic alterations in cancer patients;Rickles;Cancer Metastasis Rev.,1992

4. Hemostasis and cancer: tumour cells induce the expression of tissue factor-like procoagulant activity on endothelial cells;Maiolo;Haematologica.,2002

5. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer;Saphner;J Clin Oncol.,1991

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between epidermal growth factor receptor–tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non–small cell lung cancer;Cancer;2024-06-07

2. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer;Thrombosis Research;2023-12

3. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study;Journal of Thrombosis and Thrombolysis;2023-07-11

4. Urgences respiratoires (non infectieuses) du patient d’onco-hématologie;Revue des Maladies Respiratoires;2023-05

5. Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations;ESMO Open;2022-12